A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Guideline

  • Bleeding on Antithrombotics: Reversal Protocol 2016

    Stephan Moll, MD writes…  Our medical center (University of North Carolina Hospitals,  Chapel Hill)  has put together a comprehensive “Emergent Anticoagulation Reversal Guideline” for our local use, updated since its last edition in 2014 with information about Pradaxa® reversal (with Praxbind®).  It is  a practical, clinical how-to document (2016 PDF here ). Colleagues and hospitals are welcome to take the…

  • New Comprehensive Clinical Guidance on VTE Treatment

    Stephan Moll, MD writes… A new consensus guidance on management of venous thromboembolism (VTE) – link here – was published today, Jan 18th, 2016, in the Journal of Thrombosis and Thrombolysis.  The publication contains 13 chapters on various aspects of VTE

  • ACCP Guideline for DVT and PE Treatment: New Edition, 2016

    The ACCP Chest Guidelines have been the main guide over the last more than 2 decades for evidence-based recommendations on best management of anticoagulants for various indications, including DVT and PE.  The 10th edition of the chapter on DVT and PE management was published in Jan 2016 [ref 1]. Unfortunately, the guideline is not available for non-subscribers.

  • Two Things Physicians Should Avoid

    Stephan Moll, MD writes (Dec 17, 2014)…  The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1].

  • VTE Prophylaxis in Hospitalized Patients: Guidance Document

    Stephan Moll, MD writes (on 12/5/2014)… Venous thromboembolism (VTE) prophylaxis in hospitalized patients is important; it is also mandated by the Joint Commission [ref].  We have developed at the University of North Carolina (UNC) a guidance document (link here; UNC VTE prophylaxis guidance document) as a resource for our health care professionals to assist in…

  • Three Things We Shouldn’t Do

    Stephan Moll, MD writes…  The American Society of Hematology (ASH) has identified 3 things that physicians dealing with DVT, PE and anticoagulation should avoid – published today [ref 1].

  • Difficulty in Diagnosing Recurrent DVT – Clinical Guidance

    Stephan Moll, MD writes….  Recurrent DVT can be challenging to diagnose, as it may be difficult on Doppler ultrasound to tell chronic changes from additional new clot.  A guidance statement from the ISTH (International Society for Thrombosis and Haemostasis) published this week (May 18th, 2013) provides solid, clinically useful, evidence-based recommendations

  • Apixaban (Eliquis) – Hospital Guideline

    Stephan Moll, MD writes… Apixaban (Eliquis®) is FDA-approved for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation (Clot Connect discussion of the approval on  Dec 28th, 2012 is here).  Here is the management guideline for apixaban